UW Biostatistics Working Paper Series

9-8-2010

On Two-Stage Hypothesis Testing Procedures Via
Asymptotically Independent Statistics
James Dai
FHCRC, jdai@fhcrc.org

Charles Kooperberg
fred hutchinson cancer research center, clk@fhcrc.org

Michael L. LeBlanc
Fred Hutchinson Cancer Research Center, mleblanc@fhcrc.org

Ross Prentice
University of Washington, rprentic@whi.org

Suggested Citation
Dai, James; Kooperberg, Charles; LeBlanc, Michael L.; and Prentice, Ross, "On Two-Stage Hypothesis Testing Procedures Via
Asymptotically Independent Statistics" (September 2010). UW Biostatistics Working Paper Series. Working Paper 366.
http://biostats.bepress.com/uwbiostat/paper366

This working paper is hosted by The Berkeley Electronic Press (bepress) and may not be commercially reproduced without the permission of the
copyright holder.
Copyright © 2011 by the authors

On two-stage hypothesis testing procedures via asymptotically independent statistics
James Y. Dai
1100 Fairview Ave N, M2-C200, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109
jdai@fhcrc.org

Charles Kooperberg
Fred Hutchinson Cancer Research Center, Seattle, WA, 98109

Michael LeBlanc
Fred Hutchinson Cancer Research Center, Seattle, WA, 98109

Ross L. Prentice
Fred Hutchinson Cancer Research Center, Seattle, WA, 98109
Summary. Kooperberg and LeBlanc (2008) proposed a two-stage testing procedure to screen
for significant interactions in genome-wide association (GWA) studies by a soft threshold on
marginal associations (MA), though its theoretical properties and generalization have not been
elaborated. In this article, we discuss conditions that are required to achieve strong control of
the Family-Wise Error Rate (FWER) by such procedures for low or high-dimensional hypothesis testing. We provide proof of asymptotic independence of marginal association statistics
and interaction statistics in linear regression, logistic regression, and Cox proportional hazard
models in a randomized clinical trial (RCT) with a rare event. In case-control studies nested
within a RCT, a complementary criterion, namely deviation from baseline independence (DBI)
in the case-control sample, is advocated as a screening tool for discovering significant interactions or main effects. Simulations and an application to a GWA study in Women’s Health
Initiative (WHI) are presented to show utilities of the proposed two-stage testing procedures in
pharmacogenetic studies.
Keywords: interactions; marginal effects; filtering; pharmacogenetics; randomization; caseonly estimator.

1. Introduction
With the advent of high-throughput biotechnologies, e.g., microarray, Single Nucleotide Polymorphism (SNP) chips, and whole-genome sequencing, high-dimensional hypothesis testing has become a routine practice in exploratory biological or epidemiological studies. Statistical power in
this setting has been limited by stringent significance rules, e.g., Bonferroni correction of multiple
tests, that are required to guard against false positives arising from thousands or millions of tests.
While investigators strive to ascertain a large number of biological samples, this is often constrained
by cost and sample availability. Strategies on efficient design and analysis are therefore of critical
importance.
In genome-wide association (GWA) studies, multi-stage designs have been employed in which
all SNPs are screened first for suggestive evidence in a proportion of samples, and the most promising SNPs were tested in the next stage(s) (Satagopan et al., 2004; Prentice and Qi, 2006). Genotyping cost can be substantially reduced, yet with possibly little loss of power as compared to the
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one-stage design, whether analysis is based on the replication data only (Satagopan et al., 2004), or
combines data from multiple stages (Skol et al., 2006). Efficient analysis of genetic association data
has also been extensively studied. Notable strategies encompass addressing local dependence of human genome by haplotype analysis (Lin and Zeng, 2006; Dai et al., 2009a), imputing unmeasured
SNPs so that data from different platforms can be combined in meta-analysis (Li and Abecasis,
2006; Browning and Browning, 2007), and exploiting gene-environment independence assumption
to gain efficiency (Chatterjee and Carroll, 2005; Dai et al., 2009b). Aside from the sheer number of
tests, features of genetic inheritance of complex diseases pose additional threat to adequate power,
e.g., multiple risk alleles, each having marginally weak associations, possibly interacting with other
alleles or environmental attributes (Kraft, 2009).
When gene-gene or gene-environment interactions are targets of inference, there are ideas scattering in literature to filter out the majority of irrelevant SNPs upfront (Millstein et al., 2006; Kooperberg and LeBlanc, 2008; Murcray et al., 2008). The intuition is that, as long as the statistic used
in the filtering stage is independent of the statistic in the testing stage, we only need to correct for
the number of the tests actually passing the filtering, thus preserving power on features that are
most promising. The filtering criterion was largely formulated by biological premises, e.g., SNPs
with interactions are likely to have marginal effects (Kooperberg and LeBlanc, 2008), or gene-gene,
gene-environment independence in a case-control sample should be expected if there is no interaction (Millstein et al., 2006; Murcray et al., 2008). Theoretical justification of these procedures,
however, has not been elaborated.
In this article, we give a formal treatment of two-stage hypothesis testing procedures via independent statistics. We discuss in Section 2 the conditions that are required for such procedures
to maintain strong control of family-wise error rate (FWER) in both high-dimensional and lowdimensional testing. Through use of estimating equation theory, we present in Section 3 a unified
approach to prove the asymptotic independence of various statistics previously suggested. We discuss the utility of such procedures through examples in Section 3, that have a broader scope of
hypothesis testing than just GWA studies. In Sections 4 and 5, we present simulations and data
application to show the benefit of two-stage testing procedures.
2. A class of two-stage procedures and their strong control of FWER
Consider data from n subjects drawn from a cohort based on a prespecified sampling plan. Let
Yi denote the outcome variable, and let Xi = (Xi1 , ..., Xim ) denote a collection of m features
measured for ith subject. Occasionally, there is a low-dimensional variable of key interest, e.g., a
randomized intervention, denoted by Zi . For different subjects, the random variables (Yi , Xi , Zi )
are independent and identically distributed. Let θj , j = 1, ..., m, denote the parameter of interest.
The goal is to test m null hypotheses, H0j : θj = 0 versus H1j : θj 6= 0.
The test statistic for Hj is often formulated by asymptotically linear estimators (ALE) (Newey
and Powell, 1990; Robins et al., 1994), scaled by its estimated standard error. An estimator θ̂j of θj
√ Pn
√
′
Bij ) < ∞.
is asymptotically linear if n(θ̂j − θj ) = 1/ n i=1 Bij + op (1), E(Bj ) = 0, E(Bij
The function Bj is referred to as the influence function of θ̂j in the sense of Casella and Berger
√
(2002). By the Central Limit Theorem and Slutsky’s theorem n(θ̂j − θj ) isqasymptotically normal
ar(θ̂j ).
with mean 0 and variance E(B ′ Bij ). Define a Wald test statistic Tj = θ̂j / Vd
ij

Now consider a different set hypothesis tests: K0j : ϑj = 0 versus K1j : ϑj 6= 0. Let ϑ̂j
denote an asymptotically
q linear estimator of ϑj as defined above. A Wald test statistic is formulated
similarly, T 0 = ϑ̂j / Vd
ar(ϑ̂j ).
j
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The following two-stage testing procedure is considered: denote by α0 a prespecified screening
factor in the first stage, 0 < α0 < 1. The corresponding first-stage critical region is Γ0j = {Tj0 :
|Tj0 | > C1−α0 /2 }, where C1−α0 /2 is the 1 − α0 /2 quantile of the standard normal distribution.
Suppose there are m0 features falling in the critical region. Let 0 < α < 1, and define the secondstage rejection region Γj = {Tj : |Tj | > C1−α/2m0 }, where C1−α/2m0 is the 1−α/2m0 quantile of
the standard normal distribution. We declare a test statistically significant if Tj0 ∈ Γ0j and Tj ∈ Γj .
We show in the following theorems that with proper conditions, the two-stage testing procedure will control the FWER in the strong sense, though Bonferroni correction is only applied to
the second-stage testing. Strong control of FWER means that for any set of null hypotheses, the
probability of having at least one false positive test is less than or equal to the prespecified level α
(Holm, 1979). The proof is given in the Appendix.
T HEOREM 1. If the asymptotic distribution of θ̂j and ϑ̂k are multivariate Gaussian, and they
are uncorrelated, i.e.,

√
√
n(θ̂j − θj ), n(ϑ̂k − ϑk ) →p 0
∀ j, k ∈ {1, ..., m}
Cov

the proposed two-step procedure preserves FWER at the level α asymptotically in the strong sense,
i.e., for any non-empty index set J ⊆ {1, 2, ..., m}

limn→∞ Pr ∪j∈J (Tj0 ∈ Γ0j ∩ Tj ∈ Γj )|H0j , K0j ≤ α.

Theorem 1 requires that the set of estimators in the first stage and the set of estimators in the
second stage are jointly asymptotically independent, under the joint null hypothesis H0j , K0j . This
is a rather restrictive condition. For mutually independent features Xij , this condition reduces to
uncorrelated ϑ̂j and θ̂j . When Xij are correlated, we show in Section 3 that there are situations
where two sets of estimators are jointly asymptotically independent, e.g., Hj is on testing interactions of Xij with a randomized treatment assignment Zi , and Kj is on the marginal effect of Xij .
Theorem 1 applies regardless of the scale of hypothesis testing. When testing is high dimensional,
the conditions can be relaxed as long as there is weak dependence among Xi .

T HEOREM 2. In high-dimensional hypothesis testing, if the asymptotic distribution of ϑ̂j and
θ̂j are multivariate Gaussian and they are uncorrelated, i.e.,

√
√
n(ϑ̂j − ϑj ), n(θ̂j − θj ) →p 0
∀ j ∈ {1, ..., m},
Cov
0
and m
m →p α0 , the proposed two-step procedure preserves FWER at the level α for large m and n
in the strong sense, i.e., for any non-empty index set J ⊆ {1, 2, ..., m}

limm→∞ limn→∞ Pr ∪j∈J (Tj0 ∈ Γ0j ∩ Tj ∈ Γj )|H0j , K0j ≤ α.

Theorem 2 requires marginal asymptotic independence of Tj0 and Tj under the joint null hypothesis, which is satisfied for numerous examples in Section 3. The conditions required to obtain
m0
m →p α0 are those required by the Law of Large Numbers (LLN) for correlated data. For instance,
if


Cov I(Tj0 ∈ Γ0j |Hj0 ), I(Tk0 ∈ Γ0k |Hk0 ) → 0,

when |j − k| gets large, then the LLN for a sequence of I(Tj0 ∈ Γ0j |Kj0 ) holds as m → ∞ (White,
2001). This type of serial correlation is exactly the linkage disequilibrium pattern observed in
human genome (The International HapMap Consortium, 2005).
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Note that both theorems indicate strong control of FWER under the joint null hypotheses, H0j
and K0j . The reason is that under the joint null, the test statistics Tj0 and Tj are the centered z-scores
p √
p
√
n(θ̂j −θj )/ Vˆ2 , n(ϑ̂k −ϑk )/ Vˆ1 which are proved to be independent in the Appendix. Under
the alternative hypothesis, our simulations suggest that Tj0 and Tj are approximately independent
as well (results not shown).
With minor modification, we can show that when a fixed top m0 features, rather than a fixed
rejection region, are selected for the second-stage testing, we still have strong control of FWER.
Details are omitted. Certainly for such two-stage procedures to be useful, they should have more
power than a Bonferroni correction for all features. One necessary requirement is that alternative
hypothesis H1 should imply K1 , so that a true alternative should pass the first-stage filtering if the
sample size is sufficiently large. For example, a non-zero interaction would suggest a non-zero main
effect unless the subgroup effects exactly cancel out. Moreover, the screening statistic Tj0 should
ensure that there is high power for K1 to pass the filtering. We will discuss this point further in
simulation studies.
3. Asymptotically independent statistics
We now discuss asymptotically independent statistics and review a number of examples in two-stage
hypothesis testing. To establish the asymptotic joint distribution of ϑ̂ and θ̂, it is necessary to study
their behaviour under (potentially) misspecified models, since the model indexed by ϑ̂ may disagree
with the model indexed by θ̂, e.g., a model is misspecified if it only includes marginal association
parameters when actually there are interactions. Maximum likelihood estimation under misspecified
models was discussed in White (1982). Let θ be the set of parametersP
in the model indexed by θ,
n
and let ϑ denote the set of parameters in the model indexed by ϑ. Let i=1 U 1i = 0 be the set of
Pn
estimating equations solved for θ̂, and let i=1 U 2i = 0 be the set of estimating equations to be
solved for ϑ̂. Suppose θ is the unique solution to the estimating equations E[U 1i ] = 0, where E
denotes expectation under the true distribution. Similarly, ϑ is the unique solution to the estimating
equations E[U 2i ] = 0. Then ϑ̂ →a.s. ϑ and θ̂ →a.s. θ.
Let A1 = E[∂U 1i /∂θ], A2 = E[∂U 2i /∂ϑ], and Bkk′ = E[U ki U k′ i ], k, k ′ = 1, 2. With
√ b
√ b
suitable regularity conditions (White, 1982)
it can be shown that n(θ
− θ) and n(ϑ
− ϑ) are
P
n
asymptotically equivalent to Ak−1 n−1/2 i=1 Uki , k = 1, 2. For each k, the random vector U ki is
i.i.d. with zero mean, but for the same i, U 1i and U 2i are possibly correlated. The joint distribution
of ϑ̂ and θ̂ is established by the Cramer-Wold device. Let t be a vector of 2 scalars, t1 and t2 .
!
 −1 −1/2 Pn

√ b
n(
θ
−
θ)
U1i
A1 n
T
T
i=1
P
+ op (1)
t
= t
√ b
n
−1/2
A−1
n(ϑ − ϑ)
2 n
i=1 U2i
=

−1/2
t1 A−1
1 n

n
X

−1/2
U1i + t2 A−1
2 n

i=1

→d

−1
N (0, t21 A−1
1 B11 A1 +

n
X

U2i + op (1)

i=1
−1
t22 A−1
B
A
22 2 +
2

−1
2t1 t2 A−1
1 B12 A2 )

√

b − θ), √n(ϑ
b − ϑ) is multiThis leads to the conclusion that the limiting distribution of
n(θ
variate Gaussian with zero means and covariance matrix
 −1

−1
A1 B11 A−1
A−1
1
1 B12 A2
.
(1)
−1
−1
A−1
A−1
2 B21 A1
2 B22 A2
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To assess asymptotic independence of ϑ̂ and θ̂, we evaluate the off-diagonal element of their covari−1
ance matrix, A−1
1 B12 A2 . This provides a unified approach to evaluate asymptotic independence
among examples as followed. We first consider marginal independence between two estimators.
3.1. Marginal independence
Example 1: Consider a simple random sample with a continuous Y , e.g., a quantitative trait such as
blood pressure, and a collection of high-dimensional features X. The interest is to identify pairwise
interactions between two features, say X1 and X2 , on Y in an ordinary least square regression,

m

E[Y |X1 , X2 ] = γ0 + γ1 X1 + γ2 X2 + γ3 X1 X2 .

(2)

There are 2 pairwise interactions, which can be computationally infeasible to assess when m is
large. Kooperberg and LeBlanc (2008) suggests filtering out features without evidence of marginal
association (MA) in a univariate regression,
E[Y |X1 ] = β0 + β1 X1 .

(3)

Let X 1 denote the design matrix of (2) with n × 4 dimension, (1, X1 , X2 , X1 X2 ). Let X 2 denote
the design matrix of (3) with 2 columns, (1, X1 ). Let Y denote the vector of the outcome variable,
and β = (β0 , β1 ), γ = (γ0 , γ1 , γ2 , γ3 ). Since the OLS estimators β̂ and γ̂ have closed form,
γ̂

=

(X T1 X 1 )−1 X T1 Y ,

β̂

=

(X T2 X 2 )−1 X T2 Y ,

we can directly compute their covariance
d
Cov(γ̂,
β̂) = (X T1 X 1 )−1 X T1 X 2 (X T2 X 2 )−1 σ̂ 2 ,

where σ̂ 2 is the estimated residual variance under (2). Note that

1 0
 0 1
T
T
−1
(X 1 X 1 ) X 1 X 2 = 
 0 0
0 0




,


because (X T1 X 1 )−1 X T1 X 1 = I and X 2 are contained in X 1 . Hence


·· ··
 ·· ·· 

(X T1 X 1 )−1 X T1 X 2 (X T2 X 2 )−1 = 
 0 0 .
0 0

This implies that βˆ1 and γˆ3 are uncorrelated, and hence independent for a normally distributed Y
at any sample size.
Example 2a: Consider a case-control study for a binary outcome Y . A collection of features
X were sampled retrospectively conditional on Y . The interest is to identify features that have
pairwise interactions, similar to Example 1. The standard approach is to fit a logistic regression
with interactions,
logit{E[Y |X1 , X2 ]} =

γ0 + γ1 X1 + γ2 X2 + γ3 X1 X2 .

(4)
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Similarly, Kooperberg and LeBlanc (2008) proposed to filter out features without much marginal
association in a univariate logistic regression,
logit{E[Y |X1 ]}

= β 0 + β1 X 1 ,

(5)

though the proof was not shown explicitly.
Let β, γ, X 1 and X 2 be defined as in Example 1. Denote U 1i the score functions for (4) and
U 2i the score functions for (5). Note that
U 1i
U 2i

= X 1i (Yi − E[Yi |X1i , X2i ]),

= X 2i (Yi − E[Yi |X1i ]).

In case-control sampling, the likelihood is the retrospective distributions of covariates conditional
on disease status. Remarkably, if a standard logistic regression is fitted to case-control data, β̂1 and
γ̂1 , γ̂2 , γ̂3 are the semiparametric maximum likelihood estimators even though biased sampling is
ignored (Prentice and Pyke, 1979). The score functions for regression coefficients from the profile
likelihood are the same as U 1i and U 2i except for the intercepts.
We evaluate the terms in the covariance matrix (1). Observe that
n
o
A1 = E (X T1i X 1i )E[Yi |X 1i ](1 − E[Yi |X 1i ]) ,
o
n
B21 = E (X 1i X T2i )(Yi − E[Yi |X 1i ])(Yi − E[Yi |X 2i ]) ,
o
n
A2 = E (X T2i X 2i )E[Yi |X 2i ](1 − E[Yi |X 2i ]) .
Thus by the Central Limit Theorem and Slutsky Theorem,
−1
A−1
1 B12 A2

We have thus shown that

=

n(X T1 X 1 )−1 (X T1 X 2 )(X T2 X 2 )−1
!
n
1 Xb
b
E[Yi |X 1i ](1 − E[Yi |X 1i ])]
n i=1

!
n
1X
b i |X 1i ])(Yi − E[Y
b i |X 2i ])
(Yi − E[Y
n i=1
!
n
1 Xb
b
E[Yi |X 2i ](1 − E[Yi |X 2i ])] + op (1).
n i=1

(X T1 X 1 )−1 X T1 X 2 (X T2 X 2 )−1


·· ··
 ·· ·· 

=
 0 0 .
0 0


−1
ˆ
Therefore the lower half submatrix of A−1
1 B12 A2 is 0. This implies that β1 and γˆ3 are asymptotically uncorrelated, and thus asymptotically independent.

Example 2b: A variation of Example 2a is to replace the standard estimators of interactions in
(4) by the so-called “case-only” estimators (Piegorsch et al., 1994; Umbach and Weinberg, 1997),

http://biostats.bepress.com/uwbiostat/paper366

Two-stage testing procedures via asymptotically independent statistics

7

when the disease is rare and the two covariates, such as a gene and an environmental variable,
are independent in the population. Despite the substantial efficiency gain, case-only estimators are
generally sensitive to departures from gene-environment independence assumption (Albert et al.,
2001). In genetic studies within randomized clinical trials (RCT), however, there exists indisputable
independence between the treatment assignment and baseline covariates, including genetic variants.
Henceforth, we focus on treatment-genotype interactions in a RCT.
Consider a randomized clinical trial with N subjects. Let Yi denote the indicator variable of
whether the ith subject acquires a disease, i = 1, ..., N . Assume that Pr(Yi = 1) ≈ 0. Let Zi
denote the indicator variable of whether the treatment or the control assignment is received. Let
X = (X1 , ..., Xm ) denote a collection of high-dimensional features, m ≫ N , e.g., SNPs in a
whole-genome association study. If X were to be measured for every participant, the joint density
(Yi , Zi , Xi ) is from i.i.d. random variables. However only a proportion of cases and a proportions of
controls are sampled to collect X. We consider two logistic regressions: one regression consisting
of Y on X1 in cases and controls as in (5), the other consisting of Z on X1 in cases only:
logit{E[Z|X1 , Y = 1]} =

δ0 + δ1 X 1 .

(6)

Following the same notations, for the ith subject, the score functions can be expressed as followed:
U i1

=

U i2

=

X 1i (Yi − E[Yi |X 1i ]),

X 1i (Zi − E[Zi |X 1i , Yi = 1])1[Yi =1] ,

where X 1i is the design vector (1, x1i ). Note that U i2 = 0 if Yi = 0. The covariance of βˆ1 and
δˆ1 can again be derived using estimating equation theory. Let β = (β0 , β1 ) and γ = (δ0 , δ1 ). Note
that
n
o
B21 = E X 1i X T1i (Yi − E[Yi |X 1i ])(Zi − E[Zi |X 1i , Yi = 1])1[Yi =1]
o
n
= Pr(Yi = 1)E X 1i X T1i (1 − Pr[Yi = 1|X 1i ])(Zi − E[Zi |X 1i , Yi = 1])
o
n
= Pr(Yi = 1)EX 1 |Y=1 X 1i X T1i (1 − Pr[Yi = 1|X 1i ])EZ |X 1 ,Y=1 (Zi − E[Zi |X 1i , Yi = 1])
= 0

The second to the last equation use the law of iterated expections. Hence the off-diagonal of the
covariance matrix is zero and the proof is complete.
Example 3: So far we assume that features that have interactions should also manifest some main
effects. Counterexamples can be constructed, e.g., two environmental groups with opposite signs
of genetic effects. Another set of screening statistics can be developed to avoid this problem. In the
rare-disease scenario considered in Example 2b, the association between Z and a feature, X1 in the
combined case-control sample may reveal some clues on interactions. Let
logit{E[Z|X1 ]} =
logit{E[Y |X1 , Z]} =

τ0 + τ1 X1 .
γ0 + γ1 X1 + γ2 Z + γ3 X1 Z.

(7)
(8)

The rationale is as followed: when the disease is rare, we expect to have Z ⊥ X1 in the controls. If
there is interaction between Z and X1 , Z and X1 are dependent in the cases. Due to oversampling
of cases, Z and X1 are dependent in the combined case-control sample. Thus we can select the top
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features from the regression Z ∼ X1 for further interaction testing. This is somewhat similar to twostep procedures previously proposed for gene-gene (Millstein et al., 2006) and gene-environment
interactions (Murcray et al., 2008), though confounding of the gene-gene or gene-environment independence is always an issue in observational studies. Intuitively, because we have not used the
disease information Y to guide the screening, we do not have to spend type I error in screening. The
formal proof can be pursued similarly by estimating equation theory.
Following the notations in Example 2b, two sets of estimating equations are
U i1
U i2

=
=

X 1i (Zi − E[Zi |X 1i ]),
X 1i (Yi − E[Yi |X 1i , Zi ]),

where U i1 is the score function of (7) and U i2 is the score function of (8). So
n
o
B21 = E X 1i X T1i (Zi − E[Zi |X 1i ])(Yi − E[Yi |X 1i , Zi ])
n
o
= EZ ,X X 1i X T1i (Zi − E[Zi |X 1i ])EY |Z ,X (Yi − E[Yi |X 1i , Zi ])
= 0.
The derivation uses the law of iterated expectations, similar to that in Example 2b. Hence the
off-diagonal of the covariance matrix is zero and the proof is complete. Interestingly, asymptotic
independence does not hold when we use the case-only estimators for interactions in the second
stage. The reason might be that the information of rare diseases and the independence has been
used in formulating the first-stage estimator (7), therefore it cannot be used again in forming caseonly estimators.
Note that asymptotic independence also holds between τ̂1 and γ̂1 . So it is possible to test for
main SNP effects in the control arm. Moreover, the same proof applies if (8) is replaced by any
regression model with X1 and Z as covariates, including
logit{E[Y |X1 , Z]} = η0 + η1 X1 + η2 Z.

(9)

so that the adjusted effect of X1 could be the test of interest after being filtered by τ̂1 in (7). Since Z
is the randomized treatment assignment, the adjusted effect γ1 approximates the marginal effect β1
in (5). As τ̂1 essentially assesses deviation from baseline independence (DBI) between Z and X1 in
the case-control sample, we call it the “DBI” criterion hereafter. These results suggest that in a RCT
with a rare outcome, we can use the criterion τ1 6= 0 in (7) to screen for SNPs with (adjusted) main
effects in (9) or (8), and SNPs with interactions with the randomized treatment in (8). In Section 5,
we show in a data example in which using DBI in screening led to some interesting discoveries in
adjusted SNP effects.
The utility of DBI can be extended to scenarios where the disease is not rare and there is a known
treatment effect. We state this in the following Lemma.
L EMMA 1. Suppose a case-control sample was drawn from a randomized clinical trial with a
binary disease outcome Y and a binary treatment assignment Z. Suppose either one of the following two conditions holds: (a) the disease is rare; (b) the disease is common and Pr(Y |Z, X) 6=
Pr(Y |X), i.e., there is a treatment effect conditional on X. Denote by R the indicator of being
selected into the case-control sample. For a baseline predictor X, if we observe that
Pr(Z|X, R = 1) 6= Pr(Z|R = 1),
then
Pr(Y |X, Z) 6= Pr(Y |Z).
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The proof is straightforward and left to Appendix. In Section 4, we compare the powers of twostage procedures using MA and DBI under both rare-disease and common-disease scenarios.
Example 4: In RCTs, study endpoint is often time-to-event and primary inference is often based on
the Cox proportional hazard model by partial likelihood. The score functions for partial likelihood
take a specialized form and the arguments used to show independence in the previous examples do
not apply. When the endpoint in a RCT is rare, however, we show below that the estimator for MA
in a Cox model is asymptotically independent of a case-only estimator for interaction.
We switch to survival analysis notations for this example. Under the proportional hazard model,
the hazard function for the failure time Y associated with covariates (Z, X, ZX) is
λ( y; Z, X) = λ0 (y) exp(β0 X + β1 Z + β2 ZX),
where β0 is the main effect of genotype X, β1 is the main effect of treatment Z, β2 is the interaction, and λ0 is an unspecified baseline hazard function. When Y is subject to independent
right-censorship, we observe T = min(Y, C) and ∆ = I(Y ≤ C), where C is the censoring time.
Let (Ti , ∆i , Zi , Xi ), i = 1, ..., n be n independent replicates. Then the partial likelihood function
for β = (β0 , β1 , β1 ) is
(
)∆ i
n
Y
exp(β ′ X i )
Pn
,
L(β) =
′
j=1 Rj (Ti ) exp(β X i )
i=1

where X i is the 3 × 1 design vector, Rj (t) is the at-risk indicator I(Tj ≥ t). The corresponding
score function equals


n
X
S (1) (β, X i )
∆i X i − (0)
,
U (β) =
S (β, X i )
i=1
Pn
Pn
where S (0) (β, t) = j=1 Rj (t) exp(β ′ X j ) and S (1) (β, t) = j=1 Rj (t) exp(β ′ X j )X j . If we
fit a Cox model with only the marginal effect of X, the model may be misspecified. Let α denote the
MA parameter in the Cox model. Under misspecified Cox models, the robustPvariance-covariance
n
estimator for α̂ is A−1 (α̂)B(α̂)A−1 (α̂) (Lin and Wei, 1989), where B(α) = i=1 Wi (α)Wi (α)′ ,

 X


n
S (1) (α, Xi )
∆j Ri (Tj ) exp(α′ Xj )
S (1) (α, Xj )
Wi (α) = ∆i Xi − (0)
−
X
−
,
j
S (α, Xi )
nS (0) (α, Xj )
S (0) (α, Xj )
j=1
 (2)

n
X
S (α, Xi ) S (1) (α, Xi )S (1) (α, Xi )′
∆i
−
.
and
A(α) =
S (0) (α, Xi )
S (0) (α, Xi )2
i=1
P
Let s(r) (α, t) = E[S (r) (α, t)],P
r = 0, 1, Ni (t) = I{Ti ≤ t, ∆i = 1}, N̄ (t) = P
Ni (t). Lin and
n
n
Wei (1989) showed that n−1/2 i=1 Wi (α) is asymptotically equivalent to n−1/2 i=1 wi (α),



Z ∞
Z ∞
s(1) (α, t)
s(1) (α, Xi )
Ri (t) exp(α′ Xi )
dNi (t) −
X
−
dF̃ (t),
Xi − (0)
wi (α) =
i
s (α, Xi )
s(0) (α, t)
s(0) (α, t)
0
0

where F̃n (t) = N̄ (t)/n and F̃ (t) = E[F̃n (t)].
Now suppose one wishes to assess and compare the treatment hazard ratios stratified by the
genotype X = x valued at 0, 1, 2. The hazard rate at time T = t from randomization, may be
specified as
λ(t; Z, X) = λ0x exp(β1 Z + β2 ZX),
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so that exp(β1 ) is the treatment hazard ratio for subjects with x = 0, and exp(β2 ) indexes an
additive interaction for subjects with x = 1, 2.
Observe that
Pr(Z = 1|T = t, X)
Pr(Z = 0|T = t, X)

=
=
=

Pr(T = t|Z = 1, X)Pr(Z = 1|x)
Pr(T = t|Z = 0, X)Pr(Z = 0|X)
Pr(T ≥ t|Z = 1, X)Pr(Z = 1|x)
exp(β1 Z + β2 ZX)
Pr(T ≥ t|Z = 0, X)Pr(Z = 0|X)
Pr(Z = 1|T ≥ t, X)
exp(β1 Z + β2 ZX).
Pr(Z = 0|T ≥ t, X)

Z and X are independent by design, the event is rare and censoring rates are equal in two arms, it
will follow that
q
Pr(Z = 1|T ≥ t, X)
=
Pr(Z = 0|T ≥ t, X)
1−q
to an excellent approximation, where q is the fraction of the trial cohort assigned to the treatment. It
follows that the β1 and β2 can be estimated using logistic regression of Z on X with log(q/(1 − q))
as an “offset”. Though estimated by a logistic regression, these estimators have a hazard ratio
interpretation in this context. Note that this version of case-only estimator allows for estimation
of treatment hazard ratio in each subgroup, not just the interaction parameter in “standard” caseonly estimators in logistic regression (Piegorsch et al., 1994). See Vittinghoff and Bauer (2006) for
related work.
Let ui (β) denote the estimating functions for this case-only estimator. Following the same
argument we used in Example 2b, E[ui (β)′ wi (α)] = 0. Briefly, observe that ui (β) is based on the
distribution of Z|X, ∆ = 1 when ∆ = 1, and is zero otherwise. On the other hand, wi is on the
distribution of X|∆. This leads to zero asymptotic covariance for α̂ and β̂. We thus show that in
RCT with a rare endpoint, the estimator of the marginal association in a Cox model is independent
of the case-only estimator of the interaction. This result can be extended to Cox-model marginal
association analyses based on such cohort sampling techniques as nested case-control and casecohort sampling.

3.2. Joint independence
For two sets of asymptotically linear estimators, for instances {β̂1j , j = 1, ..., m} and {γ̂3k , k =
1, ..., m}, joint independence implies that β̂1j and γ̂3k are uncorrelated ∀j, k, since their joint distribution is multivariate Gaussian. This is a much stronger condition than no marginal correlation
between β̂1j and γ̂3j for the same j. In fact, pathological examples can be constructed to show
that merely marginal independence in the two set of estimators could yield inflated FWER when
m is small. In randomized clinical trials, however, joint independence can be achieved for estimators in Example 2a and 3 when the randomized assignment Z is involved, whether data are
from the full cohort or a case-control sample. Next we show the proof for joint independence of
{β̂1j , j = 1, ..., m} in (5) and {γ̂3k , k = 1, ..., m} in (8).
Let Z̄ denote the mean of Zi , and let X̄j denote the mean of Xij . We consider logistic regressions with centered versions of Xij and Zi :
logit{E[Yi |Xik ]} =

logit{E[Yi |Xij , Zi ]} =

β0k + β1k (Xik − X̄k ),

γ0j + γ1j (Xij − X̄j ) + γ2j (Zi − Z̄) + γ3j (Xij − X̄j )(Zi − Z̄).
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Again let β k = (β0k , β1k ) and γ j = (γ0j , γ1j , γ2j , γ3j ). Following the same notations in Example
2a, where Ui1 denote the score vector for γ, Ui2 denote the score vector for β. Denote by V the
−1
covariance matrix of β k and γ j , V = A−1
1 B12 A2 . For j 6= k, not every element of B21 is 0.
However, it is easy to see that the lower half of this 4 × 2 matrix is 0. Denote by B12,ll′ the element
of B12 in the lth row and the l′th column. Then

B12,31 = E (Zi − Z̄)(Yi − E[Yi |Xij , Zi ])(Yi − E[Yi |Xik ])
B12,41

=
=
=

B12,32

=

B12,42

=

E[(Zi − Z̄)]E {(Yi − E[Yi |Xij , Zi ])(Yi − E[Yi |Xik ])} = 0,

E (Zi − Z̄)(Xij − X̄j )(Yi − E[Yi |Xij , Zi ])(Yi − E[Yi |Xik ])

E[Zi − Z̄]E (Xij − X̄j )(Yi − E[Yi |Xij , Zi ])(Yi − E[Yi |Xik ]) = 0,

E (Zi − Z̄)(Xik − X̄k )(Yi − E[Yi |Xij , Zi ])(Yi − E[Yi |Xik ]) = 0,

E (Zi − Z̄)(Xik − X̄k )(Xij − X̄j )(Yi − E[Yi |Xij , Zi ])(Yi − E[Yi |Xik ]) = 0.

Similarly, we can show that the off-diagonal 2 × 2 submatrices of A1 are 0. A little matrix algebra
yields V23 = V24 = 0. Thus we proved the asymptotic independence of β̂1k and γ̂3j , ∀j 6=
k. We have shown previously the asymptotic independence of β̂1j and γ̂3j . This leads to strong
independence of {β̂1j , j = 1, ..., m} and {γ̂3k , k = 1, ..., m}.
Note the same proof applies to the estimators in Example 3. As Theorem 1 stated, joint independence establishes strong control of FWER by a two-stage procedure, regardless the number of
tests. As such, in a RCT where there are a number of baseline covariates, we could use both MA
and DBI to screen for interactions between treatment- and baseline covariates.
3.3. A counterexample
We review a counterexample in which the independence of two statistics does not hold, so that
an adaptive two-stage procedure would fail to preserve the type I error. This example pertains to
choice of the estimator for a gene-environment interaction in an observational study. The case-only
estimator is efficient, yet the required gene-environment independence is often subject to confounding. A naive adaptive procedure is to first test the independence of gene and environment factors
in the controls, then use the case-only estimator or the standard interaction estimator when the first
hypothesis is not rejected (Albert et al., 2001). Following the notations in Example 2b, let Z denote the environmental factor and X denote the genetic factor. We note that in the following three
regression models,
logit{E[Z|X, Y = 0]} =

ν0 + ν1 X1 ,

logit{E[Y |X, Z]} =
logit{E[Z|X, Y = 1]} =

γ0 + γ1 X + γ2 Z + γ3 XZ,
δ0 + δ1 X.

ν̂1 is independent of δ1 since they use different data, yet ν̂1 is not independent of γ3 . So using ν̂1 to
decide whether to use γ̂3 or δ̂1 will incur an inflated type I error (Albert et al., 2001).
4. Simulations
We first examine empirical correlations of various pairs of statistics in small samples by simulation.
We generated 20,000 simulated datasets from the logistic regression model (4), in which parameters
are γ = (−1, 0, 0, γ3) with varying levels of interactions γ3 = 0, 0.5, or 1. The sample sizes of
the simulated datasets were 200, 1000, and 5000. X1 and X2 were generated as bivariate normal
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Table 1. The empirical correlations for the marginal effect β̂1 and the interaction γ̂3 in Example 2a
with simple random sampling among 20,000 simulated data. X1 and X2 have a standard bivariate
normal distribution with varying degree of correlation. The parameters are from the following
models: β1 : logit{E[Y |X]} = β0 + β1 X; γ3 : logit{E[Y |X, Z]} = γ0 + γ1 X + γ2 Z + γ3 XZ.
n = 200
n = 1000
n = 5000
Estimator Z-score Estimator Z-score Estimator Z-score
γ3 = 0 cor(X1 , X2 )=0.0
−0.014 −0.014
−0.007 −0.008
−0.003 −0.004
cor(X1 , X2 )=0.4
−0.019 −0.017
−0.006 −0.006
−0.001 −0.001
cor(X1 , X2 )=0.8
−0.018 −0.015
−0.005 −0.006
0.001
0.001
γ3 = 0.5 cor(X1 , X2 )=0.0
−0.007 −0.009
−0.007 −0.007
−0.007 −0.007
cor(X1 , X2 )=0.4
0.008
0.007
0.002
0.003
−0.010 −0.009
cor(X1 , X2 )=0.8
0.004
0.004
−0.011 −0.010
0.004
0.005
γ3 = 1 cor(X1 , X2 )=0.0
−0.001 −0.002
0.005
0.006
0.005
0.005
cor(X1 , X2 )=0.4
0.008
0.008
−0.011 −0.011
−0.018 −0.018
cor(X1 , X2 )=0.8
0.003
0.005
−0.007 −0.007
−0.019 −0.019

distribution with means 0 and variances 1. We introduced a range of correlation between X1 and X2
from 0 to 0.8. Table 1 shows the empirical correlation of β̂1 and γ̂3 , and empirical correlation of their
corresponding centered z-scores in various parameter settings. The centered z-score is the centered
estimator (estimator substracted by the mean), scaled by the sandwich variance estimator. Clearly
even with a sample size of 200, the asymptotic independence holds fairly well across different levels
of interactions and different levels of covariate correlations.
We also simulated case-control samples that are nested within a randomized clinical trial (Example 2b and 3). A binary randomized treatment variable was generated from Ber(0.5), the SNP
has minor allele frequency 0.2 and diploids were formed assuming the Hardy-Weinberg equilibrium. The logistic regression model (4) with γ = (−4.5, 0, 0, γ3) was used to generate the disease
data for N = 2 × 104 , 105 , 5 × 105 . The marginal disease probability is around 0.01. Again we
varied the size of interaction at 0, 0.5 and 1. The sizes of the second-stage case-control samples
are approximately 400, 2000, 10000, with a 1:1 case-control ratio. Table 2 shows the empirical
correlations of various statistics in 20,000 simulated datasets. With sample size 400 and beyond,
the correlation of various pairs of statistics is fairly close to zero as theory predicts. The pair of
statistics in the counterexample display a consistent correlation around −0.7, confirming that using
such statistics in an adaptive testing procedure would yield an inflated type I error.
In Table 3, we assess the empirical FWER over 1000 simulated datasets, each containing 10,000
SNPs for 1000 subjects. The minor allele frequencies were randomly generated from a uniform
distribution from 0.1 to 0.5. The SNPs are either independent (ρ = 0.5) or have a serial correlation
(ρ = 0.5). A binary treatment assignment was randomly generated by Ber(0.5). The binary
disease status was generated by the logistic model (8) with γ = (−4, 0, 0, 0) or (−4, 0, log(1.5), 0),
the latter assumes a mild treatment effect. Various two-stage procedures in Example 2a, 2b and
3 were applied to screen for main effects or interactions with α0 = 0.001, 0.01, or 0.1, and α =
0.05. For each pair of statistics, we alternated the screening statistics and the testing statistics. For
example, we could use interactions as screening criteria for testing main effects. Across all settings,
FWERs are controlled at the level of 0.05; as expected, none of them falls outside of 95% confidence
intervals of 0.05.
We study in Figure 1 and Figure 2 the power performance for the procedures in simulations
with half a million independent SNPs, one of which is true alternative hypothesis and the rest are
all nulls. The SNPs were generated based on Hardy-Weinberg equilibrium. The simulation was
designed with a case-control study nested in a randomized clinical trial (Example 2b and 3). The
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Table 2. The empirical correlations of various statistics in Example 2a-3 with case-control sampling among
20,000 simulated case-control data.The parameters are from the following models: β1 : logit{E[Y |X]} =
β0 + β1 X; γ3 : logit{E[Y |X, Z]} = γ0 + γ1 X + γ2 Z + γ3 XZ; δ1 : logit{E[Z|X, Y = 1]} = δ0 + δ1 X; τ1 :
logit{E[Z|X]} = τ0 + τ1 X; ν1 : logit{E[Z|X, Y = 0]} = ν0 + ν1 X.
n = 400
n = 2000
n = 10000
Estimator Z-score Estimator Z-score Estimator Z-score
γ3 = 0 β1 : γ3
−0.004 −0.003
0.002
0.003
0.003
0.003
β1 : δ1
−0.004
0.002
0.001
0.001
−0.001 −0.001
τ1 : γ 3
−2e-4 −0.001
0.003
0.003
0.001
0.001
τ1 : γ 1
0.001
0.002
−0.004 −0.004
−0.003 −0.004
ν1 : γ 3
−0.702 −0.703
−0.706 −0.706
−0.709 −0.709
γ3 = 0.5 β1 : γ3
−0.008 −0.006
0.005
0.005
0.006
0.006
β1 : δ1
−0.004 −0.004
0.002
0.003
0.008
0.008
τ1 : γ 3
−0.018 −0.019
2e-4
0.001
−0.004 −0.004
τ1 : γ 1
0.016
0.019
−0.001 −0.001
0.007
0.007
ν1 : γ 3
−0.720 −0.722
−0.719 −0.726
−0.719 −0.719
γ3 = 1 β1 : γ3
−0.010 −0.005
0.005
0.006
−0.016 −0.016
β1 : δ1
−0.009
0.004
0.013
0.014
−0.012 −0.011
τ1 : γ 3
−0.012 −0.011
0.005
0.005
−0.004 −0.004
τ1 : γ 1
0.006
0.010
0.004
0.005
0.002
0.002
ν1 : γ 3
−0.701 −0.705
−0.705 −0.706
−0.701 −0.701

Table 3. The empirical FWER in 1000 simulations. 10,000 SNPs are simulated for 1000 cases and
1000 controls by case-control sampling. SNPs are generated either independently or with serial
correlation 0.5. The disease status is generated by the logistic model (8). The parameters are from
the following models: β1 , logit{E[Y |X]} = β0 +β1 X; γ3 , logit{E[Y |X, Z]} = γ0 +γ1 X +γ2 Z +γ3 XZ;
δ1 , logit{E[Z|X, Y = 1]} = δ0 + δ1 X; τ1 , logit{E[Z|X]} = τ0 + τ1 X. β1 → γ3 indicates using β1 for
screening, and γ3 for testing.
γ = (−4, 0, 0, 0)
γ = (−4, 0, log(1.5), 0)
α0 = 0.001 α0 = 0.01 α0 = 0.1 α0 = 0.001 α0 = 0.01 α0 = 0.1
ρ = 0 β1 → γ3
0.037
0.045
0.050
0.050
0.046
0.043
γ3 → β1
0.043
0.036
0.042
0.048
0.045
0.054
β1 → δ1
0.042
0.051
0.043
0.041
0.030
0.037
δ1 → β1
0.044
0.049
0.034
0.038
0.043
0.060
α1 → γ3
0.042
0.047
0.032
0.042
0.035
0.034
α1 → γ1
0.036
0.033
0.047
0.036
0.036
0.026
ρ = 0.5 β1 → γ3
0.044
0.046
0.046
0.053
0.040
0.039
γ3 → β1
0.046
0.048
0.050
0.043
0.040
0.047
β1 → δ1
0.052
0.050
0.043
0.051
0.051
0.044
δ1 → β1
0.057
0.044
0.051
0.043
0.051
0.045
α1 → γ3
0.041
0.034
0.039
0.046
0.045
0.046
α1 → γ1
0.047
0.037
0.048
0.045
0.043
0.040

Hosted by The Berkeley Electronic Press

J.Y. Dai, M. LeBlanc, C. Kooperberg, and R.L. Prentice

0.6
Power

0.0

0.2

0.4

0.6
0.4
0.0

0.2

Power

MA + Standard Interaction
MA + CaseOnly
DBI + Standard Interaction
Standard Interaction
Case−only

0.8

MA + Standard Interaction
MA + CaseOnly
DBI + Standard Interaction
Standard Interaction
Case−only

0.8

14

0.00

0.02

0.04

0.06

0.08

0.10

0.00

0.02

0.04

α0

0.08

0.10

MA + Standard Interaction
DBI + Standard Interaction
Standard Interaction

0.6

0.8

0.7

(b) γ = (−4, −0.5 log 2, 0, log 2)

0.9

(a) γ = (−4, 0, 0, log 2)

0.5
0.4

Power

0.1
0.0

0.2

0.3

0.2

0.5

0.3

0.6

0.7

MA + Standard Interaction
DBI + Standard Interaction
Standard Interaction

0.4

Power

0.06
α0

0.00

0.02

0.04

0.06

0.08

α0

(c) γ = (−2, 0, − log 1.5, log 2)

0.10

0.00

0.02

0.04

0.06

0.08

0.10

α0

(d) γ = (−2, − log 1.8, log 1.5, log 2)

Fig. 1. Power to detect the treatment-SNP interaction using two-stage procedures in simulations.
Assuming one of 1 million SNPs carries disease risk, the risk model takes form of logit{E[Y |X, Z]} =
γ0 + γ1 X + γ2 Z + γ3 XZ. The parameters are from the following models: MA - β1 , logit{E[Y |X]} =
β0 + β1 X; Standard Interaction - γ3 , logit{E[Y |X, Z]} = γ0 + γ1 X + γ2 Z + γ3 XZ; CaseOnly - δ1 ,
logit{E[Z|X, Y = 1]} = δ0 + δ1 X; DBI - τ1 , logit{E[Z|X]} = τ0 + τ1 X.
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Fig. 2. Power to detect the SNP main effect using two-stage procedures in simulations. Assuming
one of 1 million SNPs carries disease risk, the risk model takes form of logit{E[Y |X, Z]} = γ0 +
γ1 X + γ2 Z + γ3 XZ. The parameters are from the following models: MA - β1 , logit{E[Y |X]} =
β0 + β1 X; γ3 , Standard Interaction - logit{E[Y |X, Z]} = γ0 + γ1 X + γ2 Z + γ3 XZ; Case-Only δ1 , logit{E[Z|X, Y = 1]} = δ0 + δ1 X; DBI - τ1 , logit{E[Z|X]} = τ0 + τ1 X; Adjusted MA - η1 ,
logit{E[Y |X, Z]} = η0 + η1 X + η2 Z
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randomization ratio to the treatment arm and the control arm is 1:1, and the case-control sampling
ratio is also 1:1. The power was computed as the percentage of simulations where the SNP with the
signal was declared to be significant in 10,000 simulations. With almost half a million null tests, the
number of tests passing the first stage criterion would vary little from mα0 , so we used the second
stage cut-off C1−α/(2mα0 ) as if it was fixed in every simulation. We devised various parameter
settings and a range of α0 to study the full spectrum of operating characteristics.
Figure 1 shows the power to detect an interaction between the signal SNP (X) and the treatment
Z. Denote by N the total sample size, n the sample size for the case-control sample, p is the minor
allele frequency of the target SNP, γ is the vector of parameters in the model (8) that generates the
data. Across 4 graphs, the red curve is the power of screening main effects by β̂1 before testing
interactions using the case-only estimator (δ̂1 ), for α0 valued from 0.00001 to 0.1; the black curve
is the power of screening by main effects β̂1 before testing interactions using the standard estimator
(γ̂3 ); the green line is the power of screening by DBI τ̂1 before testing interaction (γ̂3 ). The red
horizontal dotted line is the power of testing for case-only interactions by Bonferroni correction for
half an million test; the black horizontal dotted line is the power of testing for standard interactions
by Bonferroni correction for half a million tests. These two dotted lines provide benchmarks for a
comparison of power.
In Figure 1(a), N = 50, 000, n ≈ 1000, p = 0.1, γ = (−4, 0, 0, log 2). The marginal disease
probability is around 0.02. Clearly, the case-only estimator provides a substantial lift of power on
top of the standard interaction estimator. The two-stage procedure with MA and case-only estimator
yields substantial power improvement over other procedures. The two-stage procedure with DBI
and standard interaction estimators is slightly outperformed by first screening main effects. In Figure 1(b), N = 50, 000, n ≈ 1000, p = 0.2, γ = (−4, −0.5 log 2, 0, log 2), so that the interaction
between the treatment and the SNP is qualitative, i.e., the sign of the SNP effect differs in different
treatment groups. The main effect of the SNP is negligible, which lead to poor power performance
of the two-stage procedures using main effects for an initial screen. The two-stage procedure using DBI avoids the cancellation of opposite SNP effects, thus yields a noticeable power gain over
the two-stage procedures using main effects. The best procedure in this scenario is, however, the
case-only estimator with Bonferroni correction (the dotted red line), suggesting that in rare disease
settings, case-only estimators are preferable wherever possible. We show in Example 3 that DBI
can be extended to settings with common diseases, as long as there is a treatment effect. In Figure
1(c), N = 50, 000, n ≈ 1000, p = 0.2, γ = (−2, 0, − log 1.5, log 2). The disease probability is
roughly 10% and there is a mild treatment effect and a strong interaction effect. Case-only estimators are no longer eligible, yet the two-stage procedure using MA to filter still performs better
than the two-stage procedure using DBI, both improving upon the standard interactions. In Figure
1(d), N = 50, 000, n ≈ 1000, p = 0.3, γ = (−2, − log 1.8, log 1.5, log 2). There is a qualitative
interaction and thus a small marginal SNP effect, hence the two-stage procedure using MA to screen
has little power to detect the true interaction, while screening by DBI in this scenario yields much
better power.
Figure 2 shows the power to detect the SNP effect using two-stage procedures either using
interaction or DBI as the screening criterion. The labels for various procedures are similar to those
in Figure 1, except that the SNP effect, either marginal or adjusted for treatment, is of interest after
screening. In Figure 2(a), N = 50, 000, n ≈ 1000, p = 0.1, γ = (−4, log 1.5, 0, log 1.5). Clearly
in this setting, the best procedure is to test the marginal effect directly, two-stage procedures using
either interaction or DBI in screening does not perform comparably. The reason is that testing for
interaction, even with case-only estimator, is more costly to sample size than testing for main effect,
therefore screening by interactions for marginal effects does not help when there is a moderate size
of interaction. In Figure 2(b), N = 50, 000, n ≈ 1000, p = 0.1, γ = (−4, − log 1.8, log 0.8, log 2).
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Since the marginal SNP effect is small and the interaction is fairly big, using interaction or DBI
to find marginal effect yields much better power than one-stage Bonferroni correction for MA or
adjusted MA.
Taking collectively, each of the proposed two-stage procedures has unique niche in power performance. There are situations where none of them improves power upon the one-stage all-SNP
Bonferroni test, see Figure 1(b) and Figure 2(a). It is useful to screening by MA for interactions,
since testing main effect is generally more powerful than testing interaction, so that a SNP having
interaction is likely to have high probability to pass the filter. However when there are qualitative
interactions, which might be not common, the two-stage procedure using MA does not perform
well since the marginal effect is small. The DBI criterion offers an alternative screening procedure
which can improve power in this setting, see Figure 1d. It appears less useful to screen for marginal
effects by interactions or DBI, unless there are qualitative interactions (Figure 2(b)). In any case the
marginal effect is usually of primary interest, so we may well have good power to test all SNPs.
4.1. optimal α0
Clearly in Figure 1 and 2, an optimal α can be achieved, since more tests passing the first stage
will incur more penalty by Bonferroni correction. For simulations with half a million SNPs in
Figure 1 and 2, the optimal α0 for power performance is fairly small, in the range of 0.0001 ∼
0.001. Analytically, it is possible to find the optimal α0 for a hypothesized disease risk model and
a sampling plan, since power to detect a feature can be written out approximately,
Pr(Tj0 ∈ Γ0j , Tj ∈ Γj |H1j ) ≈ Pr(Tj0 > C1−α0 /2 |H1j )Pr(Tj > C1−α/(2mα0 ) |H1j ).
With prior assumptions on an alternative hypothesis, the asymptotic distribution of Tj0 and Tj under H1j can be derived for a fixed sample size, so that an optimal α0 can be computed. Alternatively, power simulations can be conducted using our R-package powerGWASinteraction
from CRAN to obtain the optimal α0 . In any case, it is important to note that we need to set α0 fixed
before performing hypothesis testing. Data-adaptive selection of α0 will undermine error control.
5. Data application
The Women’s Health Initiative (WHI), one of the largest studies of postmenopausal women’s health
in the U.S., is composed of four randomized clinical trials (CT) and an observational study (OS). An
elevated invasive breast cancer risk was found among women assigned to estrogen plus progestin,
with suggestive evidence of risk reduction among women assigned either to estrogen-alone or to a
low-fat dietary pattern. To discover the genetic variants that may influence the risk, perhaps jointly
with the interventions, WHI launched a genome-wide association study with a three stage design
(Prentice and Qi, 2006). In the third stage, a total of 9039 SNPs were selected from previous
stages or other studies, and were genotyped among 2,166 invasive breast cancer cases in the CT
and 1:1 matched controls. Primary analyses have been presented recently (Prentice et al., 2009,
2010). Seven SNPs in the fibroblast growth factor receptor 2 (FGFR2) met criteria for genomewide significance. Recognizing limited power in detecting interactions, the investigators focused
the search for treatment-genotype interactions to the top seven SNPs ranked by MA (Prentice et al.,
2009, 2010), as well as a number of SNPs that have been reported in the literature to be associated
with breast cancer (Huang et al., 2010). Since invasive breast cancer is a rare event in the study,
the investigators used the case-only estimators described in Example 4. A number of SNPs showed
suggestive evidence of interactions with one or more interventions. The analyses presented here are
exploratory and supplementary to the findings from these primary analyses.
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Table 4. The results of two-stage procedures applied to the WHI GWAS, using DBI as a screening criterion. Four SNPs out of the top 50 SNPs ranked by the DBI criterion reach statistical
significance in testing the adjusted marginal SNP effect.
rs7705343
rs13159598
rs9790879
rs4415084
OR p-value
OR p-value
OR p-value
OR p-value
E-alone α̂1 1.5823
0.0006 1.5217
0.0014 1.4701
0.0035 1.4269
0.0063
All trials η̂1 1.1672
0.0006 1.1653
0.0007 1.1649
0.0007 1.1695
0.0005
E-alone
δ̂1 1.5231
0.0298 1.4657
0.0444 1.3842
0.0907 1.3832
0.0936

Our results justified the focused search for interactions in a subset of SNPs ranked by top
marginal association. In addition, we also explored the two-stage procedures using the DBI criterion to look for significant marginal effects and interactions (Example 3). This is done separately
for each of the 4 randomized trials. In the first stage, we ranked SNPs by p-values for DBI. We
tested for main effects and interactions for the top 50 SNPs ranked by DBI. Among the top 50 SNPs
ranked by DBI in the E-alone trial, there are four SNPs that pass the Bonferroni correction for 50
SNPs in testing for adjusted SNP effect. Table 3 shows the parameter estimates of these 4 SNPs.
The adjusted additive SNP effect η̂1 was estimated from case-control data for all 4 trials, adjusted
for matching variables, important baseline predictors and randomization indicators. The effect size
(odds ratio) is fairly modest around 1.16. In the E-alone trial, there seems to be a weak interaction
between the SNPs and the treatment. The effect sizes of the interactions (case-only estimator δ̂1 )
are around 1.4 ∼ 1.5.
Interestingly, these four SNPs are all located in the MRPS30 gene which have been shown to
have suggestive evidence of interaction with multiple clinical interventions (Huang et al., 2010),
though the findings there are guided by prior studies. None of them would reach the genome-wide
significance level for either marginal effect or interaction, yet they reach the FWER level of 0.05 for
marginal association by our two-stage procedure. The reason might be that these four SNPs have
weak main effects and weak interactions with the E-alone intervention. The DBI criteria seem to
synthesize these weak effects and prioritizes them for further testing. This data example suggests
that two-stage procedures can be used as data-adaptive tool, as opposed to candidate genes from
prior studies, for discovering novel genes affecting disease risk. Certainly this search strategy only
serves as a supplement to the standard one-stage Bonferroni test, since it missed the seven SNPs in
the FGFR2 gene.
6. Discussion
We studied conditions that are required to maintain strong control of FWER for a class of twostage hypothesis testing procedures previously proposed. We provided a unified approach to prove
asymptotic independence by estimating equation theory. Two types of screening statistics are discussed, one is based on marginal association (MA) and the other is based on deviation from baseline
independence (DBI). In the majority of simulation settings, one or both of the proposed procedures
outperform the standard one-stage testing with Bonferroni correction.
The impact of these results is profound to discovering baseline features that influence treatment
effect in a RCT, whether they are low or high-dimensional. In randomized clinical trials, subgroup
analyses are heavily criticized as having low power to detect interactions in general, which could
be further exacerbated by data-adaptive procedures. Our results suggest that one could select predictors with evidence of MA or with evidence of DBI to test for interactions, without spending type
I error in finding these candidate predictors. We expect that the two-stage procedures will be most
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useful to discovering interaction in pharmacogenetic studies, where it is almost certain that these
studies have low power to detect interactions. In fact, we are involved in a GWA study within the
WHI clinical trials as part of the Genomics and Randomized Trials Network (GARNET) program
(www.garnetstudy.org) in which we plan to use this strategy. Using interactions or DBI to
screen for marginal effect appears less powerful in general, at most serving as exploratory supplement to primary analyses. In any case, it is worthwhile to attempt these two-stage procedures and
the standard 1-stage Bonferroni test, while splitting FWER among them.
The asymptotic independence of the two-stage test statistics can be extended beyond the examples presented. Indeed, for any estimator of parameters in a generalized linear model (GLM), the
score function can be written in a form of X(Y − E[Y|X]) = 0. The proof in Section 3 applies
immediately to the independence of estimators of MA and interaction. Thus the proposed two-stage
procedure can be applied to any GLM outcome, e.g., Poisson counts. We show in Example 4 that
approximation can be made for survival data in RCT with a rare event, so that the independence
can be carried over to Cox partial likelihood. For survival data with a common event, however, the
proposed two-stage procedures do not work in general. In future study, we intend to investigate the
possibility of asymptotic independence using parametric survival analysis.
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8. Appendix
8.1. Proof of Theorem 1
P ROOF. With mild regularity conditions, standard estimating equation theory imply that
√
n(ϑ̂k − ϑk ) →d N (0, V1 ),
√
n(θ̂j − θj ) →d N (0, V2 ),
where V1 and V2 are asymptotic variances which can be estimated by their respective empirical
averages, V̂1 and V̂2 . By the Law of Large Number, V̂1 and V̂2 are consistent estimators.
Since
√

√
Cov
n(ϑ̂k − ϑk ), n(θ̂j − θj ) → 0
as n → ∞,
and

we derive that

√
√
n(ϑ̂k − ϑk )
n(ϑ̂k − ϑk )
√
p
= op (1),
−
V1
V̂1
√
√
n(θ̂j − θj )
n(θ̂j − θj )
√
p
−
= op (1),
V2
V̂2





√
n(ϑ̂k −ϑk )

√

V̂1
√
n(θ̂j −θj )

√

V̂2




 →d N



0
0

 

1 0
,
.
0 1
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q
q
Since Tk0 = ϑ̂k / V̂1 /n and Tj = θ̂j / V̂2 /n, this implies Tk0 and Tj are asymptotically independent ∀j, k under the global null hypothesis.
We now prove the main result. Observe that m0 is a random variable taking values at 0, 1, ..., m.
Let Ik denote a set of k distinct integers from {1, ..., m}, that index the hypotheses passing the filter
in the first stage. Let Ik denote the collection (set) of all possible Ik . Note that

limn→∞ Pr ∪j∈J (Tj0 ∈ Γ0j ∩ Tj ∈ Γj )|H0j , K0j
m X
X

 

= limn→∞
Pr ∩j∈(J∩Ik ) (Tj0 ∈ Γ0j |K0j ) ∩ ∪j∈(J∩Ik ) (Tj ∈ Γj |H0j )
= limn→∞

k=1 Ik ∈Ik
m X
X

k=1 Ik ∈Ik

≤ limn→∞
≤ limn→∞
≤ α

m X
X

k=1 Ik ∈Ik
m
X

X

k=1 Ik ∈Ik



Pr ∩j∈(J∩Ik ) (Tj0 ∈ Γ0j |K0j )] Pr ∪j∈(J∩Ik ) (Tj ∈ Γj |H0j )


Pr ∩j∈(J∩Ik ) (Tj0 ∈ Γ0j |K0j )]


 X


j∈(J∩Ik )


Pr ∩j∈(J∩Ik ) (Tj0 ∈ Γ0j |K0j )] α

(10)



Pr |Tj | ≥ C1−α/2k |H0j (11)


(12)

(13)

The equality (10) holds by the asymptotic independence, the inequality (11) uses the Bonferroni
inequality, (12) uses the fact that the size of the set {j : j ∈ (J ∩ Ik )} is less than or equal to k, and
(13) holds because
m X
X

Pr ∩j∈(J∩Ik ) (Tj0 ∈ Γ0j |K0j )] = 1
k=0 Ik ∈Ik

if we denote by I0 the empty set.

2

8.2. Proof of Theorem 2
P ROOF. The proof of asymptotic independence of Tj0 and Tj under the global null hypothesis
is same as that in Theorem 1. Observe that
m0 =

m
X
j=1

I(Tj0 ∈ Γ0j |Kj0 ).

Unless Tj0 s are independent, E[ m0
m ] is generally not equal to α0 . However if
prove the main result as followed:

m0
m


limm→∞ limn→∞ Pr ∪j∈J (Tj0 ∈ Γ0j ∩ Tj ∈ Γj )|H0j , K0j

≤ limm→∞ limn→∞

= limm→∞ limn→∞

J
X
j=1

J
X
j=1


Pr (Tj0 ∈ Γ0j ∩ Tj ∈ Γj )|H0j , K0j


Pr Tj0 ∈ Γ0j |K0j Pr (Tj ∈ Γj |H0j )

→p α′0 , we can

(14)

(15)
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J
1 X
 mα
= limm→∞ limn→∞
Pr Tj0 ∈ Γ0j |K0j
m
 m0
j=1
≤ α0

= α.

α
α0

21

(16)

The inequality (14) uses Bonferroni inequality, (15) uses the asymptotic independence of Tj0 and
Tj , (16) holds because
J
1 X  0
Pr Tj ∈ Γ0j |H0j ≤ α0 ,
m j=1
and by Slutsky’s Theorem

mα
α
→p
.
m0
α0
2

8.3. Proof of Lemma 1
P ROOF. (a) If the disease is rare, Pr(Z|X, R = 1) 6= Pr(Z|R = 1) implies Pr(Z|X, Y = 1) 6=
Pr(Z|Y = 1), hence Pr(Y |X, Z) 6= Pr(Y |Z).
(b) If the disease is common and Pr(Y |Z, X) = Pr(Y |Z),
Pr(X|Y, Z) =

Pr(Y |X, Z)Pr(X|Z)
= Pr(X|Z) = Pr(X).
Pr(Y |Z)

This implies Pr(X|Y ) = Pr(X). Now
Pr(Z, X|Y )

Pr(Y |Z, X)Pr(Z)Pr(X)
Pr(Y )
Pr(Y |Z)Pr(Z)Pr(X)
=
Pr(Y )
= Pr(Z|Y )Pr(X)
=

= Pr(Z|Y )Pr(X|Y ).
Hence Z ⊥ X|Y . Since the sampling depends on Y soly, this implies that Z and X are independent
in the selected case-control samples, i.e.,
Pr(Z|X, R = 1) = Pr(Z|R = 1).
Note that if Pr(Y |X, Z) = Pr(Y |X), the same argument leads to the conclusion that Z and X are
independent in the selected case-control sample. So we need the condition Pr(Y |X, Z) 6= Pr(Y |X)
to ensure that it is possible to observe Pr(Z|X, R = 1) 6= Pr(Z|R = 1).
2
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